Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 1Classical hematology 1

Conditions

Breast Neoplasms 523Neoplasms 436Carcinoma, Non-Small-Cell Lung 409Prostatic Neoplasms 325Colorectal Neoplasms 312Lung Neoplasms 259Multiple Myeloma 226Neoplasm Metastasis 194Leukemia, Myeloid, Acute 180Pancreatic Neoplasms 176Ovarian Neoplasms 174Melanoma 146Squamous Cell Carcinoma of Head and Neck 137Carcinoma, Hepatocellular 117Stomach Neoplasms 114Carcinoma, Renal Cell 114Endometrial Neoplasms 110Recurrence 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Head and Neck Neoplasms 109Lymphoma 108Lymphoma, Non-Hodgkin 104Glioblastoma 104Brain Neoplasms 100Uterine Cervical Neoplasms 95Urinary Bladder Neoplasms 93Hematologic Neoplasms 92Triple Negative Breast Neoplasms 90Glioma 87Leukemia, Lymphocytic, Chronic, B-Cell 86

Interventions

thymoglobulin 1luspatercept 1fludarabine 1Tacrolimus 1Rituximab 1Mycophenolic Acid 1Dexamethasone 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
beta-Thalassemia × 30 days × Clear all
NCT05736419 2026-06-03

A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
24 enrolled
Classical hematology

Anemia, Sickle Cell, Thalassemia, beta-Thalassemia

NCT04064060 2026-05-28

A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials

Celgene

Phase 3 Recruiting
665 enrolled
Myeloid

Myelodysplastic Syndromes, Myeloproliferative Disorders, beta-Thalassemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡